Kornimate/medical-research-clean huggingface dataset:
effects on ocular parameters of myopic eyes after orthokeratology in myopic children

Conditions: Myopia

Summary: effects on ocular parameters of myopic eyes after orthokeratology in myopic children

1.the primary objective of the current study is to investigate changes in uncorrected visual acuity, diopter, accommodation, peripheral refraction, iop, tear film quality, corneal thickness, corneal topography, corneal biomechanical parameters, objective optical quality, corneal and conjunctiva sensitivity and choroidal thickness for children with different diopters after wearing orthokeratology lenses; 2. through measure long-term changes of these parameters, including corneal topography, axial length, peripheral refraction, objective optical quality and choroidal thickness, to explore occurrence and development regularity of myopia.

Eligibility criteria:
inclusion criteria: * 1. subjects were 6-16 years of age; 2.had no other ocular diseases aside from refractive error and no keratoconus (confirmed by pre-treatment corneal topography); 3. had an intraocular pressure (iop) of \<21 mmhg; 4. had an with-the- rule astigmatism (axes 180 ± 30) ≤ 1.50 d; 5.had a best corrected visual acuity（bcva） ≤0.00 log mar units in both eyes (snellen equivalent to 20/20); exclusion criteria: * 1. had binocular vision problems; 2.use medications that might affect refractive development; 3.had history of ortho-k or contact lens wear; 4. ocular surface diseases and other eye diseases which can cause abnormalities of ocular surface; 5. patients with histories of ocular injury or surgery; 6. corneal staining and decentration of lens after wearing ortho-k.
corona-like illness: did we got it before who announcement of the disease?

Conditions: COVID-19

Summary: a pneumonia of unknown cause detected in wuhan, china was first reported to the who country office in china on 31 december 2019. the outbreak was declared a public health emergency of international concern on 30 january 2020. the spread and severity of the disease is variable from one country to another. our team as well as many reports suggested that in some countries a " flu like illness but much worse" was described in october, november and early in december before the who announcement. was it covid-19?


Eligibility criteria:
inclusion criteria: * all subject except excluded group exclusion criteria: * subject diagnosed as covid-19 positive and their contacts

Keywords: covid-19 corona-like illness who announcement survey igg
a phase 4 study to assess the effects of aripiprazole versus other atypical antipsychotics in the treatment of schizophrenic patients with metabolic syndrome

Conditions: Metabolic Syndrome; Schizophrenia

Summary: 258 patients who have been treated for at least 3 months with oral olanzapine, risperidone or quetiapine in the treatment of schizophrenia and currently presenting with metabolic syndrome, will be randomized to: i) aripiprazole for 16 weeks, with flexible dosing within a range of 10 to 30 mg once daily (qd); or ii) continue for 16 weeks on the same atypical antipsychotic treatment prior to the study enrollment.


Eligibility criteria:
inclusion criteria: patients: * with schizophrenia being treated with olanzapine, risperidone, or quetiapine for at least 3 months * with diagnosis of metabolic syndrome * not treated for 1 of the parameters of metabolic syndrome
in-market utilisation of liraglutide used for weight management in europe

Conditions: Metabolism and Nutrition Disorder; Obesity

Summary: this study is conducted in europe. the aim of this study is to investigate usage of liraglutide for weight management in clinical practice.


Eligibility criteria:
inclusion criteria: * initiation of liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg (initiation is defined as no prescription of the same brand within the previous 12 months) * informed consent obtained before any study-related activities. study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability of the study exclusion criteria: -patients or physicians who previously participated in interventional studies for liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg will not be eligible to participate in the study -for the full study, sites and patients included in the pilot will be excluded
creatine or vitamin d supplementation in persons with spinal cord injury undergoing resistance training

Conditions: Spinal Cord Injuries

Summary: the purpose of this study is to determine the effects of creatine monohydrate or vitamin d supplementation on strength gains following a traditional resistance training program for adults with spinal cord injury.


Eligibility criteria:
inclusion criteria: * spinal cord injury * minimum time since injury: 3 months exclusion criteria: * participation in resistance training programmes in the previous 6 months * creatine or vitamin d supplementation in the previous 6 months
lycopene in healthy male participants

Conditions: Healthy, no Evidence of Disease; Prostate Cancer

Summary: this randomized phase i trial is studying the side effects and best dose of lycopene in healthy male participants. chemoprevention is the use of certain drugs to keep cancer from forming. the use of lycopene, a substance found in tomatoes, may prevent prostate cancer.

objectives: i. compare the toxicity and safety of 2 different doses of oral lycopene in healthy male participants. ii. compare the pharmacokinetics of 2 different doses of this drug in these participants. iii. determine the toxicity and pharmacokinetics needed to proceed to a large phase ii/iii study in men at high risk for prostate cancer. outline: this is a randomized, crossover study. participants are randomized to 1 of 2 treatment arms. arm i: participants receive high-dose oral lycopene once or twice a day for 14 days. after 2 weeks of a lycopene-free period, participants crossover and receive high-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days. arm ii: participants receive low-dose oral lycopene once or twice a day for 14 days. after 2 weeks of a lycopene-free period, participants crossover and receive low-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days. treatment continues in the absence of unacceptable toxicity. participants adhere to dietary restrictions for 2 weeks at baseline, 2 weeks during study treatment, and 2 weeks during pharmacokinetic sampling. blood samples are collected periodically at baseline and during study treatment for pharmacokinetic studies. projected accrual: a total of 20 participants will be accrued for this study.

Eligibility criteria:
inclusion criteria: * healthy volunteers judged to be in good medical condition based on history and physical exam * karnofsky performance status 100% * ast and alt ≤ 75 iu/l * bilirubin ≤ 2.0 mg/dl * creatinine ≤ 1.5 mg/dl * hemoglobin ≥ 13.0 g/dl * wbc ≥ 4,000/mm³ * platelet count ≥ 150,000/mm³ and ≤ 400,000/mm³ * must be within height and weight standards identified by metropolitan life scales * nonsmoker (for ≥ 3 months) * no history of alcohol abuse * no history of gastrointestinal malabsorption or other condition that could affect drug absorption * no history of a psychiatric condition * no chronic medical condition * no active history of any of the following: * cancer * liver disease * cardiovascular disease * renal disease * diabetes mellitus * other illnesses that, in the opinion of the investigator, could represent a threat for the participants life * no allergy to tomato-based products * no lycopene in the diet for ≥ 14 days * at least 4 weeks since prior and no other concurrent experimental medications * no concurrent participation in another experimental study * no concurrent use of regular prescription medication or over-the-counter medications * no concurrent vitamin, mineral, or herbal supplements
vitamin b12 supplementation study

Conditions: Vitamin B12 Deficiency

Summary: we hope to learn the clinical and functional signs of sub-clinical vitamin b12 deficiency and its response to supplementation in non-anemic, non-pregnant, and non-lactating women in rural mexico. vitamin b12 is important in hematopoiesis, neuro-cognitive functions and genetic integrity. however vitamin b12 is only found in animal source foods therefore a large segment of the population in developing countries and those practicing vegetarianism are at risk of deficiency of the vitamin. this information will help decide weather supplementation with vitamin b12 is necessary in such populations for public health reasons.


Eligibility criteria:
inclusion criteria: * women age 20-59, apparently healthy, no severe b12 deficiency exclusion criteria: * pregnancy, lactation, anemia and disease states

Keywords: b12 deficiency methylmalonic acid homocystein vitamin b12 supplementation intervention
norepinephrine prophylaxis for postspinal anesthesia hypotension in parturients with preeclampsia

Conditions: Adverse Effect

Summary: the purpose of this study is to investigate the efficacy and safety of norepinephrine for prophylaxis against postspinal anesthesia hypotension in parturients with preeclampsia undergoing cesarean section.

preeclampsia, which affects 5% to 7% of parturients, is a significant cause of maternal and neonatal morbidity and mortality. because of constricted myometrial spiral arteries with exaggerated vasomotor responsiveness, though blood pressure in parturients with preeclampsia are apparently higher than healthy parturients, placental hypoperfusion is more common. spinal anesthesia is still the preferred mode of anesthesia in parturients with preeclampsia for cesarean section. in preeclampsia parturients, spinal anesthesia improve intervillous blood flow (provided that hypotension is avoided) which contribute to increase placental perfusion. even so, 17-26% parturients with preeclampsia experienced postspinal anesthesia hypotension due to the extensive sympathetic block that occurred with spinal anesthesia. as a potential substitute drug for phenylephrine and ephedrine, norepinephrine has gained traction for use in parturients undergoing cesarean section. but the efficacy and safety in parturients with preeclampsia is still unknown. the purpose of this study is to investigate the efficacy and safety of norepinephrine for prophylaxis against post-spinal anesthesia hypotension in parturients with preeclampsia undergoing cesarean section.

Eligibility criteria:
criteria: inclusion criteria: * 18-45 years * primipara or multipara * singleton pregnancy ≥32 weeks * american society of anesthesiologists physical status classification ii to iii * scheduled for cesarean section under spinal anesthesia exclusion criteria: * baseline blood pressure ≥180 mmhg * body height \< 150 cm * body weight \> 100 kg or body mass index (bmi) ≥ 40 kg/m2 * eclampsia or chronic hypertension * hemoglobin \< 7g/dl * fetal distress, or known fetal developmental anomaly

Keywords: norepinephrine postspinal anesthesia hypotension preeclampsia cesarean section
saliva and plasma endocannabinoids concentrations according to feeding status and body mass index

Conditions: Obesity

Summary: up till now, the evaluation of the endocannabinoid system (ecs) in humans needs invasive procedures. the investigators managed in the lab to determine the levels of endocannabinoids in a small number of subjects. the aim of the study is to confirm that salivary is a useful tool to evaluate the activity of the ecs both in normal weight and obese subjects that are characterised by a hyperactivity of the system. therefore, the first objective of the study is to compare the fasting level of salivary anandamide between 12 obese patients and 12 normal weight subjects.

the prevalence of obesity keeps increasing in industrialized countries. however, efficient treatments of this chronic disease are still lacking. a better understanding of the systems that regulate energy balance and eating behavior is mandatory to better understand the disease and find appropriate treatments. the endocannabinoid system (ecs) which comprises cannabinoid receptors, such as cb1 and cb2, endogenous ligands (named endocannabinoids) and specific biosynthetic and degradative pathways is a key system in the regulation of energy balance and obesity. obesity is characterised by an hyperactivity of the system both in animal and humans. moreover, the activity of the ecs is influenced by feeding status although only one study has only been performed in humans. the investigation of the ecs in humans needs invasive procedure (blood sampling or adipose or liver biopsy). the aim of our study is to evaluate a new tool for the ecs evaluation in humans i e the determinations of saliva concentration of endocannabinoids both in normal weight and obese subjects before and after food intake. blood and saliva sampling will be performed after an overnight fast, one hour before, just before and one hour after a lunch in12 normal weight subjects and 12 obese characterised with anthropometric (weight, height, bmi (body mass index), waist circumference, blood pressure) and metabolic (glycaemia, insulin, lipid profile, liver profile) evaluations. the endocannabinoids concentrations will be measured with mass spectrometry in blood and saliva and gut hormones (pyy (peptide yy) and ghrelin) will be measured in plasma.

Eligibility criteria:
inclusion criteria: obese patients : * age between 18 and 65 yrs * bmi (body mass index) \> 30 kg/m² * signed inform consent before any investigation related to the study * no smoker normal weight subjects : * age between 18 and 65 yrs * bmi between 18 and 25 kg/m² * signed inform consent before any investigation related to the study * no smoker exclusion criteria: * treatments that could interfere with the endocannabinoid system (anxiolytics, anticonvulsivants, antidepressants drugs) * pregnancy, breast feeding

Keywords: obesity endocannabinoids
single-center prospective evaluation of sickle cell patient care in the chu brugmann emergency department

Conditions: Sickle Cell Disease

Summary: sickle cell disease is a serious disease that is life-threatening for patients being homozygous for the ss form or heterozygous for the sc or bthal forms. the chu brugmann hospital currently regularly treats about 70 homozygous adult patients and this number is in constant augmentation. the age average of the patients is below 30. the hospital developed a close collaboration with the queen fabiola kids university hospital to optimize the transition of young sickle cell patients from the pediatric to the adult network. the emergency care of sickle cell patients remains a source of worry. even with a correct treatment (hydroxy-urea or exsanguineous transfusions), patients suffer from frequent sickle cell disease crisis when stress or infection cause hemolysis. the pain level is intolerable and causes emergency hospital admission (2 to 3 crisis per patient per year on average). the crisis are more frequent with poor compliance to the treatments. there are several obstacles to the rapid and optimal management of these patients: * fear of causing addiction to heavy pain releaf products (high dosis of morphine) * lack of biological parameters for the determination of the crisis severity. the prognostic value of the lactate dehydrogenase (ldh) level in a vaso-occlusive crisis was recently stressed while activation of the coagulation, translated by the elevation of various parameters including the rate of dd dimers, seemed associated with clinical complications. the deleterious role of increased oxidative stress has also been recently demonstrated in patients with sickle cell disease, opening new therapeutic avenues. this study aims to prospectively evaluate the management of sickle cell patients being admitted in the emergency department for a vaso-occlusive crisis. the level of satisfaction of the patients will be measured. the investigators will also evaluate the predictive value of several routine biological parameters regarding the severity of the crisis, including the values of nitrous albumin (pna) as marker of oxydative stress. this last dosage will be made in collaboration with the team of dr wayenberg and pr bottari in grenoble.


Eligibility criteria:
inclusion criteria: * any sickle cell disease patient being admitted inside the emergency department of the brugmann hospital for a vaso-occlusive crisis, having signed the informed consent form and being able to fill in the analogic visual questionnaire (eva). exclusion criteria: * patients not being able to sign the informed consent form or fill in the analogic visual questionnaire (eva)

Keywords: sickle cell disease vaso-occlusive crisis emergency management
early lung function trajectories: comparison between infants with and without intrauterine growth restriction.

Conditions: Intrauterine Growth Retardation (IUGR); Lung Function Tests; Preterm Infant; Respiratory Monitoring

Summary: during intrauterine life, some babies are smaller or grow less than expected. this fetal growth abnormality, called fetal growth restriction (fgr), can be diagnosed by ultrasound. since there are currently no curative treatments for this condition, nor methods to optimize the growth of babies in the womb, the only effective strategy is intensive monitoring of fetal conditions, accompanied by early planning of delivery. the diagnosis of early fgr (i.e. diagnosed before 32 weeks of gestation) confers a greater risk of short- and long-term respiratory problems. the study aims to examine the association between parameters that can be assessed during pregnancy by ultrasound, such as the estimate of lung volumes, the thickness and contractility of the diaphragm, and cardiac kinetics, and any perinatal complications and respiratory function in the first years of life of premature infants, both with and without evidence of fetal growth pathology. therefore, the study is divided into two phases: a prenatal and a postnatal phase. the study includes two groups of patients: 1. study group: fetuses and preterm infants with a prenatal history of fgr; 2. control group: preterm infants without a prenatal history of fgr followed during neonatal follow-up. pregnant women with fetuses with fgr are followed at the ultrasound clinics dedicated to growth pathology. these pregnancies usually receive weekly ultrasound monitoring, which includes a doppler study of the maternal and fetal circulation and an estimate of fetal weight every two weeks. cardiotocographic monitoring is also planned once or twice a week, depending on fetal well-being. the child will be assessed from a respiratory point of view during hospitalization and subsequently in the outpatient clinic, as required by clinical practice. he/she will undergo respiratory function tests. visits are scheduled at 3, 6, 12 and 24 months of corrected age, during which at least two respiratory function tests will be performed. in addition, routine clinical data (personal data, medical history, blood tests, biological and instrumental tests) present in the medical record of the child will be collected. data from preterm infants without fetal growth restriction will be collected after informed consent. these infants are routinely followed at our institution and undergo clinical assessment and lung function tests in the first two years of life as previously indicated.


Eligibility criteria:
inclusion criteria: * fetuses and infants born before 32 weeks of gestation, with and without fetal growth restriction exclusion criteria: * lack of informed consent * need for palliative care * major malformations

Keywords: lung volume measurements pulmonary function test preterm birth intrauterine growth retardation oxygen saturation/physiology
the effects of 8-week choline, betaine, and folic acid supplementation on plasma homocysteine concentration during guanidinoacetic acid loading in young healthy volunteers

Conditions: Hyperhomocysteinemia

Summary: a methyl-group acceptor such as guanidinoacetic acid (gaa) could induce hyperhomocysteinemia with the effects of gaa expected to be dose-dependent. due to the fact that hyperhomocysteinemia is thought to be an independent risk factor for cardiovascular and neurodegenerative diseases, different dietary agents were used in the past for the treatment of elevated total plasma homocysteine (t-hcy), e. g. betaine, choline (betaine precursor) or folic acid. in the context of gaa loading the question arises whether intake of betaine, choline (betaine precursor) or folic acid during gaa loading could affect plasma t-hcy in healthy humans. forty healthy physically active men and women aged 20 to 30 years will take part in this gaa-controlled, double-blind and parallel-group intervention study. subjects will be allocated to four randomly assigned trials, with treatment lasting for 8 weeks and washout period of 28 days. the 4 test treatment-groups will include test1 (gaa only), test2 (gaa, choline, b6, b12 and folic acid), test3 (gaa, betaine, b6, b12 and folic acid) and test4 (gaa, b6, b12 and folic acid). plasma t-hcy will be the primary outcome measure assessed every second week throughout the study. plasma b-vitamins and blood and urine metabolites (gaa, creatine, methionine, arginine) will be secondary outcome measures along with adverse-effects indicators assessed every second week throughout the study. selected body composition indicators will be obtained at 0, 2, 8 and 12 weeks throughout the study to monitor the effects of experimental treatments on body hydration and protein synthesis. this research will test the hypothesis that a combination of gaa with homocysteine lowering nutrients attenuates the elevation of t-hcy, and will further display the size-effect of each additive used.


Eligibility criteria:
inclusion criteria: * healthy male and non-pregnant females * moderately physically active * aged 20 to 30 years * not currently taking any dietary supplement for the past 2 months exclusion criteria: - total plasma homocysteine above 15.5 µmol/l

Keywords: remethylation human subjects clinical trial b-vitamin creatine